Clinical Trial: SHR-1701 Combined With Chemotherapy for Gastric or Gastroesophageal Junction Adenocarcinoma With Peritoneal Metastasis

U.S., Feb. 4 -- ClinicalTrials.gov registry received information related to the study (NCT07384234) titled 'SHR-1701 Combined With Chemotherapy for Gastric or Gastroesophageal Junction Adenocarcinoma With Peritoneal Metastasis' on Jan. 26.

Brief Summary: This study is a prospective, randomized, two-cohort trial designed to evaluate the efficacy and safety of two regimens in the treatment of gastric or gastroesophageal junction adenocarcinoma with peritoneal metastasis: SHR-1701 combined with intravenous and intraperitoneal paclitaxel plus S-1, or SHR-1701 combined with CAPOX.

Study Start Date: Jan. 31

Study Type: INTERVENTIONAL

Condition: Gastric Adenocarcinoma and Gastroesophageal Junction Adenocarcinoma

Intervention: DRUG: SHR-1701...